A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy Study to Evaluate the Efficacy, Safety, and Tolerability of Carbavance (Meropenem/Vaborbactam) Compared to Piperacillin/Tazobactam in the Treatment of cUTIs, Including AP, in Adults

Trial Profile

A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy Study to Evaluate the Efficacy, Safety, and Tolerability of Carbavance (Meropenem/Vaborbactam) Compared to Piperacillin/Tazobactam in the Treatment of cUTIs, Including AP, in Adults

Completed
Phase of Trial: Phase III

Latest Information Update: 30 May 2017

At a glance

  • Drugs Meropenem/vaborbactam (Primary) ; Levofloxacin; Piperacillin/tazobactam
  • Indications Pyelonephritis; Urinary tract infections
  • Focus Registrational; Therapeutic Use
  • Acronyms TANGO 1
  • Sponsors Rempex Pharmaceuticals
  • Most Recent Events

    • 30 May 2017 According to The Medicines Company media release, data from this trial will be featured in presentations at the American Society for Microbiologys ASM Microbe 2017.
    • 25 Apr 2017 Results assessing clinical outcomes, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases.
    • 25 Apr 2017 Results assessing the safety and efficacy presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top